Cross-sectional study for COVID-19-related mortality predictors in a Brazilian state-wide landscape: the role of demographic factors, symptoms and comorbidities
Emanuele Gustani Gustani-Buss,
Carlos E Buss,
Luciane R Cavalli,
Carolina Panis,
Felipe F Tuon,
Joao P Telles,
Franciele A C Follador,
Guilherme W Wendt,
Léia C Lucio,
Lirane E D Ferreto,
Isabela M de Oliveira,
Emerson Carraro,
Lualis E David,
Andréa N C Simão,
Angelica B W Boldt,
Maria Luiza Petzl-Erler,
Wilson A Silva,
David L A Figueiredo
Affiliations
Emanuele Gustani Gustani-Buss
Bioinformatics Laboratory, Institute for Cancer Research, IPEC, Guarapuava, Brazil
Carlos E Buss
Bioinformatics Laboratory, Institute for Cancer Research, IPEC, Guarapuava, Brazil
Luciane R Cavalli
Postgraduate Program in Biotechnology Applied to Child and Adolescent Health at FPP, Faculdades Pequeno Príncipe, Curitiba, Brazil
Carolina Panis
Laboratory of Tumor Biology, Western Paraná State University-UNIOESTE, Cascavel, Brazil
Felipe F Tuon
Laboratory of Emerging Infectious Diseases, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil
Joao P Telles
Laboratory of Emerging Infectious Diseases, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil
Franciele A C Follador
Department of Life Sciences,Postgraduate Program in Applied Health Sciences, Western Paraná State University-UNIOESTE, Francisco Beltrão, Brazil
Guilherme W Wendt
Department of Life Sciences,Postgraduate Program in Applied Health Sciences, Western Paraná State University-UNIOESTE, Francisco Beltrão, Brazil
Léia C Lucio
Department of Life Sciences,Postgraduate Program in Applied Health Sciences, Western Paraná State University-UNIOESTE, Francisco Beltrão, Brazil
Lirane E D Ferreto
Department of Life Sciences,Postgraduate Program in Applied Health Sciences, Western Paraná State University-UNIOESTE, Francisco Beltrão, Brazil
Isabela M de Oliveira
New Arrangements for Research and Innovation - Genomics-Novos Arranjos de Pesquisa e Inovação - Genômica (NAPI-Genômica), Araucária Foundation – FAAP-PR, Curitiba, Parana, Brazil
Emerson Carraro
New Arrangements for Research and Innovation - Genomics-Novos Arranjos de Pesquisa e Inovação - Genômica (NAPI-Genômica), Araucária Foundation – FAAP-PR, Curitiba, Parana, Brazil
Lualis E David
Virology Laboratory, Midwestern Parana State University-UNICENTRO, Guarapuava, Brazil
Andréa N C Simão
Laboratory of Research in Applied Immunology, Department of Pathology, Clinical Analysis and Toxicology, State University of Londrina-UEL, Londrina, Brazil
Angelica B W Boldt
New Arrangements for Research and Innovation - Genomics-Novos Arranjos de Pesquisa e Inovação - Genômica (NAPI-Genômica), Araucária Foundation – FAAP-PR, Curitiba, Parana, Brazil
Maria Luiza Petzl-Erler
New Arrangements for Research and Innovation - Genomics-Novos Arranjos de Pesquisa e Inovação - Genômica (NAPI-Genômica), Araucária Foundation – FAAP-PR, Curitiba, Parana, Brazil
Wilson A Silva
Institute for Cancer Research IPEC, Guarapuava, Brazil
David L A Figueiredo
New Arrangements for Research and Innovation - Genomics-Novos Arranjos de Pesquisa e Inovação - Genômica (NAPI-Genômica), Araucária Foundation – FAAP-PR, Curitiba, Parana, Brazil
Objective The Brazilian state of Paraná has suffered from COVID-19 effects, understanding predictors of increased mortality in health system interventions prevent hospitalisation of patients. We selected the best models to evaluate the association of death with demographic characteristics, symptoms and comorbidities based on three levels of clinical severity for COVID-19: non-hospitalised, hospitalised non-ICU ward and ICU ward.Design Cross-sectional survey using binomial mixed models.Setting COVID-19-positive cases diagnosed by reverse transcription–PCR of municipalities located in Paraná State.Patients Cases of anonymous datasets of electronic medical records from 1 April 2020 to 31 December 2020.Primary and secondary outcome measures The best prediction factors were chosen based on criteria after a stepwise analysis using multicollinearity measure, lower Akaike information criterion and goodness-of-fit χ2 tests from univariate to multivariate contexts.Results Male sex was associated with increased mortality among non-hospitalised patients (OR 1.76, 95% CI 1.47 to 2.11) and non-ICU patients (OR 1.22, 95% CI 1.05 to 1.43) for symptoms and for comorbidities (OR 1.89, 95% CI 1.59 to 2.25, and OR 1.30, 95% CI 1.11 to 1.52, respectively). Higher mortality occurred in patients older than 35 years in non-hospitalised (for symptoms: OR 4.05, 95% CI 1.55 to 10.54; and for comorbidities: OR 3.00, 95% CI 1.24 to 7.27) and in hospitalised over 40 years (for symptoms: OR 2.72, 95% CI 1.08 to 6.87; and for comorbidities: OR 2.66, 95% CI 1.22 to 5.79). Dyspnoea was associated with increased mortality in non-hospitalised (OR 4.14, 95% CI 3.45 to 4.96), non-ICU (OR 2.41, 95% CI 2.04 to 2.84) and ICU (OR 1.38, 95% CI 1.10 to 1.72) patients. Neurological disorders (OR 2.16, 95% CI 1.35 to 3.46), neoplastic (OR 3.22, 95% CI 1.75 to 5.93) and kidney diseases (OR 2.13, 95% CI 1.36 to 3.35) showed the majority of increased mortality for ICU as well in the three levels of severity jointly with heart disease, diabetes and CPOD.Conclusions These findings highlight the importance of the predictor’s assessment for the implementation of public healthcare policy in response to the COVID-19 pandemic, mainly to understand how non-pharmaceutical measures could mitigate the virus impact over the population.